GENERATE BIOMEDICINES INC (GENB) — insider trading
Health Care · NASDAQ
GENERATE BIOMEDICINES INC (GENB) has 38 reported SEC Form 4 insider transactions in our data, including 8 open-market purchases among the most recent 38 (latest 2026-03-04).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | Nally Michael | Director, Officer (Chief Executive Officer) | Open-market purchase | 20,000 | $12.00 | $240.0K | Form 4 |
| 2026-03-02 | Nally Michael | Director, Officer (Chief Executive Officer) | Conversion of derivative (derivative) | 1,000,000 | $0.00 | $0 | Form 4 |
| 2026-03-02 | Nally Michael | Director, Officer (Chief Executive Officer) | Conversion of derivative | 658,327 | — | — | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative (derivative) | 2,109,704 | $0.00 | $0 | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative (derivative) | 1,265,822 | $0.00 | $0 | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative (derivative) | 2,531,644 | $0.00 | $0 | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative (derivative) | 2,109,704 | $0.00 | $0 | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative (derivative) | 2,953,586 | $0.00 | $0 | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative (derivative) | 1,265,822 | $0.00 | $0 | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative (derivative) | 843,881 | $0.00 | $0 | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative (derivative) | 1,500,000 | $0.00 | $0 | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative (derivative) | 17,016,215 | $0.00 | $0 | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative (derivative) | 18,483,785 | $0.00 | $0 | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Open-market purchase | 1,562,500 | $16.00 | $25.00M | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Open-market purchase | 1,562,500 | $16.00 | $25.00M | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Open-market purchase | 1,562,500 | $16.00 | $25.00M | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative | 2,777,752 | — | — | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative | 2,777,752 | — | — | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative | 987,491 | — | — | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative | 13,702,224 | — | — | Form 4 |
| 2026-03-02 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Conversion of derivative | 12,723,940 | — | — | Form 4 |
| 2026-03-02 | Silvers Jason | Officer (President & CFO) | Open-market purchase | 1,000 | $16.00 | $16.0K | Form 4 |
| 2026-03-02 | Silvers Jason | Officer (President & CFO) | Open-market purchase | 500 | $16.00 | $8.0K | Form 4 |
| 2026-03-02 | Silvers Jason | Officer (President & CFO) | Open-market purchase | 500 | $16.00 | $8.0K | Form 4 |
| 2026-03-02 | Grous Beth | Officer (Chief People Officer) | Open-market purchase | 300 | $16.00 | $4.8K | Form 4 |
| 2026-02-26 | Nally Michael | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 844,595 | $0.00 | $0 | Form 4 |
| 2026-02-26 | Nally Michael | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 844,595 | $0.00 | $0 | Form 4 |
| 2026-02-26 | Grigoryan Gevorg | Officer (Chief Technology Officer) | Grant / award / vesting (derivative) | 196,368 | $0.00 | $0 | Form 4 |
| 2026-02-26 | Grigoryan Gevorg | Officer (Chief Technology Officer) | Grant / award / vesting (derivative) | 295,608 | $0.00 | $0 | Form 4 |
| 2026-02-26 | AFEYAN NOUBAR; Flagship Pioneering, LLC; Flagship VentureLabs VI Manager LLC; Flagship Pioneering Fund VI General Partner LLC; Flagship Pioneering Fund VII General Partner LLC; Nutritional Health LTP Fund General Partner LLC; Flagship Pioneering Special Opportunities Fund II General Partner LLC; FPN General Partner LLC | Director, 10% owner | Grant / award / vesting (derivative) | 29,561 | $0.00 | $0 | Form 4 |
| 2026-02-26 | Silvers Jason | Officer (President & CFO) | Grant / award / vesting (derivative) | 274,493 | $0.00 | $0 | Form 4 |
| 2026-02-26 | Silvers Jason | Officer (President & CFO) | Grant / award / vesting (derivative) | 295,608 | $0.00 | $0 | Form 4 |
| 2026-02-26 | Simonian Nancy A | Director | Grant / award / vesting (derivative) | 29,561 | $0.00 | $0 | Form 4 |
| 2026-02-26 | Martin Sean | Officer (Chief Legal Officer & GC) | Grant / award / vesting (derivative) | 190,034 | $0.00 | $0 | Form 4 |
| 2026-02-26 | Lee Laurie Anne | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 42,230 | $0.00 | $0 | Form 4 |
| 2026-02-26 | ARNOLD FRANCES | Director | Grant / award / vesting (derivative) | 29,561 | $0.00 | $0 | Form 4 |
| 2026-02-26 | Grous Beth | Officer (Chief People Officer) | Grant / award / vesting (derivative) | 114,020 | $0.00 | $0 | Form 4 |
| 2026-02-26 | Vessey Rupert | Director | Grant / award / vesting (derivative) | 29,561 | $0.00 | $0 | Form 4 |
Ask the chat about GENB's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: GENERATE BIOMEDICINES INC (GENB).
Last updated 2026-03-04 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.